key: cord-0812414-an1wfsvk
authors: Gandolfini, Ilaria; Zanelli, Paola; Palmisano, Alessandra; Salvetti, Daniel; Parmigiani, Alice; Maltzman, Jonathan S.; Labate, Claudia; Fiaccadori, Enrico; Cravedi, Paolo; Maggiore, Umberto
title: Anti‐HLA and anti‐SARS‐CoV‐2 antibodies in kidney transplant recipients with COVID‐19
date: 2021-02-26
journal: Transpl Int
DOI: 10.1111/tri.13829
sha: c23f750ba6323835a409cd82731983465b6ccaa9
doc_id: 812414
cord_uid: an1wfsvk

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and its associated illness coronavirus disease 2019 (COVID-19) have severely affected organ transplant recipients, with all-cause mortality rates exceeding 20% (1, 2). Although no clear guidelines exist on how to adjust immunosuppression, most centers reduce anti-rejection drugs to facilitate the T and B cell response against the virus.

To the Editors, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and its associated illness coronavirus disease 2019 (COVID-19) have severely affected organ transplant recipients, with all-cause mortality rates exceeding 20% [1, 2] . Although no clear guidelines exist on how to adjust immunosuppression, most centers reduce anti-rejection drugs to facilitate the T-and B-cell response against the virus. However, this maneuver may unleash the anti-donor immune response as well. Even if immunosuppression is not modified, infection episodes per se promote a proinflammatory state that may lead to an increased risk of rejection or of anti-HLA antibody development [3] . In most of the reports published so far, acute rejection episodes were uncommon during COVID-19 infection despite immunosuppression reduction [4] . However, no study has formally addressed the relationship between COVID-19 and the development of anti-HLA antibodies.

We recently showed that kidney transplant recipients with COVID-19 display a broad activation of B-cell subsets, together with detectable serum anti-SARS-CoV-2 IgM and IgG as early as 10 days after the onset of clinical symptoms [5] , suggestive of a broad activation of the humoral response. Herein, we tested the hypothesis that COVID-19 associates with the development of anti-HLA antibodies in kidney transplant recipients.

The transplant center of the Parma University Hospital, Parma, Italy, actively follows up approximately 800 kidney transplant recipients. From March 1 to December 2, 2020, 17 of these patients were diagnosed with symptomatic SARS-CoV-2 infection (confirmed by RT-PCR testing). Thirteen patients were admitted at Parma University Hospital, Parma, Italy, and four were followed up as outpatients. Fourteen patients survived for more than 30 days after admission, and 7 of them had available serum that was collected at 3 months postinfection. In our center, kidney transplant recipients undergo regular measurements of donor-specific antibodies (DSA) and panel-reactive antibodies (PRA) and all the seven included patients had their measurements done no more than three months prior to infection. We used the sera collected at 3 months postinfection to measure anti-HLA (by Luminex Technology, One Lambda) and anti-SARS-CoV-2 IgM and IgG antibodies (JusChek; Acro Biotech, Rancho Cucamonga, CA, USA).

At diagnosis, all patients showed pneumonia and signs of systemic inflammations, such as elevated C-reactive protein (CRP), IL-6, and D-Dimer (Table 1) . During COVID-19, six patients underwent reduction in immunosuppression that was resumed at discharge (Table 1) . Two patients developed acute kidney injury, but serum creatinine fully recovered at 3 months after COVID-19 infection (Table 1 ). Contrary to our hypothesis, none of the patients developed anti-HLA antibodies, but all of them had detectable anti-SARS-CoV-2 IgM and IgG (Table 1) . One patient (patient 2) had anti-donor antibodies before COVID-19, but neither their MFI nor their HLA specificities increased after COVID-19.

To the best of our knowledge, this is the first series of patients with serial anti-HLA antibody measurements. Despite significant reduction in immunosuppression in most of our patients and a systemic proinflammatory state associated with COVID-19, no patients developed signs of increased alloimmune response. This finding is in line with prior evidence that COVID-19 does not associate with disease relapses even in patients with autoimmune conditions [6] . The mechanisms behind this unexpected phenomenon are unknown and worth investigating. Our analysis is still preliminary, and we cannot exclude that COVID-19 does in fact increase the risk of DSA development. Although multiple series have reported a relatively low risk of acute rejection in kidney transplant recipients with COVID-19, careful monitoring of alloimmune response during COVID-19 should still be advised, especially in transplant recipients undergoing significant reduction in immunosuppressive therapy.

PC is supported by NIH NIAID Grant 3U01AI063594-17S1.

COVID-19-related mortality in kidney transplant and dialysis patients: results of the ERACODA collaboration

COVID-19 and kidney transplantation: results from the TANGO international transplant consortium

Trends in immune cell function assay and donor-specific HLA antibodies in kidney transplantation: a 3-year prospective study

COVID-19-related mortality during the first 60 days after kidney transplantation

Evidence of potent humoral immune activity in COVID-19-infected kidney transplant recipients

Coronavirus disease 2019 (COVID-19) in autoimmune hepatitis: a lesson from immunosuppressed patients

JSM receives research support from One Lambda/ Thermo Fisher. The other authors of this manuscript declare no funding and no conflict of interest.